Skip to main content

Human IL-29/IFN-lambda 1 Antibody

R&D Systems, part of Bio-Techne | Catalog # AF1598

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
AF1598
AF1598-SP

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human, Mouse

Applications

Validated:

Neutralization, Western Blot

Cited:

Bioassay, ELISA Development, Neutralization, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human IL-29/IFN-lambda 1
Gly20-Thr200
Accession # Q8IU54

Specificity

Detects human IL-29/IFN-lambda 1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 25% cross-reactivity with recombinant human (rh) IL‑28A and rhIL-28B is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human IL-29/IFN-lambda 1 Antibody

IL‑29/IFN-lambda 1 Inhibition of EMCV‑induced Cytopathy and Neutralization by Human IL‑29/IFN-lambda 1 Antibody.

IL‑29/IFN-lambda 1 Inhibition of EMCV‑induced Cytopathy and Neutralization by Human IL‑29/IFN-lambda 1 Antibody.

Recombinant Human IL-29/ IFN-lambda 1 (Catalog # 1598-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepato-cellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IL-29/IFN-lambda 1 (40 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-29/IFN-lambda 1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1598). The ND50 is typically 0.2-1.0 µg/mL.

Applications for Human IL-29/IFN-lambda 1 Antibody

Application
Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Human IL-29/IFN-lambda 1 (Catalog # 1598-IL)

Neutralization

Measured by its ability to neutralize IL‑29/IFN-lambda 1 inhibition of EMCV-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line [Sheppard, P. et al. (2003) Nat. Immunol. 4:63]. The Neutralization Dose (ND50) is typically 0.2-1.0 µg/mL in the presence of 40 ng/mL Recombinant Human IL‑29/IFN-lambda 1.

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-29/IFN-lambda 1

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity) (1-3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon, The expression of IL-28A, B, and IL‑29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor  beta (IL-10 R beta) and a novel IL-28 receptor  alpha (IL-28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory region of the target genes. Human IL-29 cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 19 aa signal peptide and a 181 aa mature protein, which is a monomer in solution. It shares 67% and 69% aa sequence identity with human IL-28A and IL-28B, respectively.

References

  1. Vilcek, J. (2003) Nature Immunol. 4:8.
  2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
  3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.

Long Name

Interleukin 29

Alternate Names

IFN-lambda 1, IL29

Entrez Gene IDs

282618 (Human)

Gene Symbol

IFNL1

UniProt

Additional IL-29/IFN-lambda 1 Products

Product Documents for Human IL-29/IFN-lambda 1 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human IL-29/IFN-lambda 1 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...